Trial Profile
A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety Assessor Blinded Trial in Adult Subjects Comparing Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Subjects Undergoing Short Surgical Procedures in Out-patient Surgicenters
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Rocuronium bromide (Primary) ; Sugammadex (Primary) ; Suxamethonium chloride
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 08 Oct 2015 New trial record